Real-life effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in people with Type 2 diabetes (T2D) according to baseline HbA1c and BMI
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00085089" target="_blank" >RIV/00023001:_____/24:00085089 - isvavai.cz</a>
Result on the web
<a href="https://link.springer.com/content/pdf/10.1007/s13300-024-01644-0.pdf" target="_blank" >https://link.springer.com/content/pdf/10.1007/s13300-024-01644-0.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s13300-024-01644-0" target="_blank" >10.1007/s13300-024-01644-0</a>
Alternative languages
Result language
angličtina
Original language name
Real-life effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in people with Type 2 diabetes (T2D) according to baseline HbA1c and BMI
Original language description
Introduction: This study aimed to evaluate the effect of baseline body mass index (BMI) and glycated hemoglobin (HbA1c) on the effectiveness and safety of initiating iGlarLixi (insulin glargine 100 U/ml and lixisenatide) in people with type 2 diabetes (T2D) in routine clinical practice. Methods: We pooled patient-level data from 1406 people with inadequately controlled T2D, initiating a 24-week iGlarLixi treatment. Analysis sets were based on baseline BMI and HbA1c. In the BMI set, 894 (64%) people had a BMI >= 30 kg/m(2) and 510 (36%) a BMI < 30 kg/m(2); in the HbA1c set, 615 (44%) people had an HbA1c >9%, 491 (35%) between 8 and 9%, and 298 (21%) < 8%. Results: After initiating iGlarLixi, HbA1c decreased in all participants, with the greatest least-squares mean reduction at 2.15% from baseline to week 24 in those with baseline HbA1c > 9% (using a mixed model for repeated measures). Overall, mean +/- standard deviation body weight decreased by 1.9 +/- 4.8 kg, with the most prominent loss of 2.6 +/- 4.9 kg recorded in people presenting with obesity. Reported hypoglycemia rates were low across all groups. Conclusions: Initiation of iGlarLixi in people with uncontrolled T2D is effective and safe in clinical practice, across different baseline HbA1c and BMI categories.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Diabetes therapy
ISSN
1869-6953
e-ISSN
1869-6961
Volume of the periodical
15
Issue of the periodical within the volume
11
Country of publishing house
DE - GERMANY
Number of pages
14
Pages from-to
2337-2350
UT code for WoS article
001312117900002
EID of the result in the Scopus database
2-s2.0-85204152478